Of course it it - if the generic Copax had already been approved, MNTA's stock price would be at 20 & TEVA would have lost 20 points. Hey Shortie, that what you could be looking at ... Teva losing 20 points - how is them apples?
We will hear the same drivel "working with the FDA'. Cutting other programs cuz no relief in sight. Unless they have to now do patient trials.
weeks or months to wait - not a big deal. I'll be happy if it happens before EOY. Still plenty of money to be made by/on MNTA. ...
Wow - you think the government cares how much the taxpayers lose. The CP has to be thoroughly vetted given it is the first in the new biosimilar gene game. Thus it will be months before any approval which will go to Momenta for an at risk launch for the exclusivity period.
While it must respond within 180 days, the FDA does not have to respond to a citizen petition before it rules on a related ANDA. 7 The FDA’s policy is to assess a citizen petition prior to approving a related ANDA, but the agency does not always issue its formal response to the petition before ruling on the ANDA.
Wrong CP has ZERO impact on approval US taxpayers are losing tens of millions every delay due to this frivolous actions of TEVA and the stall tactics
No way- with the new CP just filed it will be months for all parties to put their input together for the FDA to say it gave everyone reasonable consideration.
Its called Greening. Keep on extending your 7 year licence to infinity. They have to thank the USA for the over abundance of Lawyers and legalese that has permeated the medical world. Reformation is now impossible.!
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
TEVA makes 9million dollars a day from this product. One would expect their legal team to at least try to earn their keep.A one month delay from generic competition would pay a few salaries,bonuses,and
stock option grants to senior management-hey we all know they deserve it. Yes even when the stock price plummets these guy's will probably get a raise.
they can try, -i agree with erporgene - the fat lady is singing -waiting on approval. I bought MNTA shares as I think it's possible there will only be one version of generic approved, and that I bet is MNTA. If I remember correctly, MNTA has an in with the FDA- The FDA has turned to it in the past for assistance. It should be interesting to see how this whole thing plays out.. I'm betting on MNTA....GLTA
Hilarious - a company that makes its living on generics trying to fight against competition for one of its own drugs - what it will get is a taste of its own medicine, so to speak.....a citizens petition -what's next? how bout a bunch of naked ladies standing in front of the FDA with signs saying "naked female genetalia against generic copaxone".....
Yes, BUT the big picture is still FDA approval which the new ( filed today CP) is still trying to uphold, Even if ALL patents expired last week/ month/year- no FDA approval means no sales for MNTA or Mylan, that is exactly what the new filling by TEVA is trying to do. So TEVA has to think that there is some chance that they can try to prevent approval of generics, by requiring full phase studies for efficacy. Which would give then exclusivity for many more years.
Afterthought- Nobody tries this hard to keep competition out unless you think there is a possibility of approval and market share takeaway. Time will tell
Court decided in mnta's favor and teva is on its hands and knees hoping for a long shot US Supreme Court reversal of that appellate decision, nevertheless MNTA has built up a huge inventory ready to release generic copaxone this month